SAN FRANCISCO–(BUSINESS WIRE)–FibroGen, Inc. (FibroGen), announced today that interim results from an ongoing open-label Phase 2 clinical study to evaluate FG-3019 as a treatment for idiopathic pulmonary fibrosis (IPF) continue to suggest that the investigational drug has the potential to stabilize and improve fibrosis in patients with the disease. The results substantiate earlier results reported in an oral presentation at the European Respiratory Society Annual Congress in September 2012.
“A substantial subset of IPF patients who received FG-3019 in the Phase 2 open label study experienced stabilization or improvement of lung fibrosis, based on computer-assisted high-resolution radiographic scores of lung fibrosis”
“A substantial subset of IPF patients who received FG-3019 in the Phase 2 open label study experienced stabilization or improvement of lung fibrosis, based on computer-assisted high-resolution radiographic scores of lung fibrosis,” noted Frank H. Valone, M.D., Chief Medical Officer of FibroGen. “This observation of IPF fibrosis improvement is without clinical precedent and directly challenges the widely held belief that improvement in fibrosis is not a therapeutic possibility. Data from the Phase 2 FG-3019 study also suggest a correlation between improved fibrosis and improved pulmonary function. This evidence supports our belief in the potential clinical impact of FG-3019 across a number of IPF clinical outcomes.”
Read the entire article at:
http://www.businesswire.com/news/home/20131126006311/en/FibroGen-Announces-Observations-Disease-Stabilization-Improvement-Interim#.VCnKcM90xhE
For more information about Idiopathic Pulmonary Fibrosis please visit our websitewww.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday
